163 related articles for article (PubMed ID: 35786377)
21. Effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19: A systematic review and meta-analysis.
Dai MF; Xin WX; Kong S; Ding HY; Fang L
Thromb Res; 2023 Jan; 221():105-112. PubMed ID: 36502592
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 thromboprophylaxis. New evidence.
Ferrandis R; Sierra P; Gomez-Luque A
Rev Esp Anestesiol Reanim (Engl Ed); 2024 Jan; 71(1):34-47. PubMed ID: 37678450
[TBL] [Abstract][Full Text] [Related]
23. Parenteral and Oral Anticoagulant Treatment for Hospitalized and Post-Discharge COVID-19 Patients: A Systematic Review and Meta-Analysis.
Tunjungputri RN; Tetrasiwi EN; Mulansari NA; Harimurti K; Nelwan EJ
Acta Med Indones; 2022 Apr; 54(2):190-209. PubMed ID: 35818663
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Clinical Impact of Thromboprophylaxis in Patients With COVID-19 Following Hospital Discharge.
Courtney LA; Trujillo TC; Saseen JJ; Wright G; Palkimas S
Ann Pharmacother; 2022 Sep; 56(9):981-987. PubMed ID: 35021920
[TBL] [Abstract][Full Text] [Related]
25. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
MacDougall K; Spyropoulos AC
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252423
[TBL] [Abstract][Full Text] [Related]
26. Thrombosis in COVID 2022: An Updated Narrative Review of Current Literature and Inpatient Management.
Muthiah A; Ohnigian S; Reagan JL; Hsu A
R I Med J (2013); 2022 Aug; 105(6):36-40. PubMed ID: 35881999
[TBL] [Abstract][Full Text] [Related]
27. Use of Anticoagulants in COVID-19: A Review.
Ngu S; Smith JK; Goldin M
Am J Ther; 2022 Jul; 29(4):e425-e436. PubMed ID: 35476050
[TBL] [Abstract][Full Text] [Related]
28. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry.
Giannis D; Allen SL; Tsang J; Flint S; Pinhasov T; Williams S; Tan G; Thakur R; Leung C; Snyder M; Bhatia C; Garrett D; Cotte C; Isaacs S; Gugerty E; Davidson A; Marder GS; Schnitzer A; Goldberg B; McGinn T; Davidson KW; Barish MA; Qiu M; Zhang M; Goldin M; Matsagkas M; Arnaoutoglou E; Spyropoulos AC
Blood; 2021 May; 137(20):2838-2847. PubMed ID: 33824972
[TBL] [Abstract][Full Text] [Related]
29. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.
Fontana P; Casini A; Robert-Ebadi H; Glauser F; Righini M; Blondon M
Swiss Med Wkly; 2020 Jun; 150():w20301. PubMed ID: 32640479
[TBL] [Abstract][Full Text] [Related]
30. The management of venous thromboembolism in hospitalized patients with COVID-19.
Spyropoulos AC
Blood Adv; 2020 Aug; 4(16):4028. PubMed ID: 32841342
[TBL] [Abstract][Full Text] [Related]
31. A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19.
Amani-Beni R; Kermani-Alghoraishi M; Darouei B; Reid CM
Egypt Heart J; 2023 Aug; 75(1):72. PubMed ID: 37596465
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
[TBL] [Abstract][Full Text] [Related]
33. Late-onset of pulmonary embolism following hospitalization for COVID-19 despite thromboprophylaxis: a report of two cases.
Brem FL; Missaoui Z; Arghal M; Rasras H; Aichouni N; Skiker I; Ouafi NE; Zakaria B
Pan Afr Med J; 2021; 38():226. PubMed ID: 34046131
[TBL] [Abstract][Full Text] [Related]
34. Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients.
Berkman SA
Postgrad Med; 2021 Aug; 133(sup1):51-63. PubMed ID: 33435758
[TBL] [Abstract][Full Text] [Related]
35. Extended-duration thromboprophylaxis after ventral hernia repair: a risk model to predict venous thrombotic events after hospital discharge.
Kumar SB; Mettupalli D; Carter JT
Hernia; 2022 Jun; 26(3):919-926. PubMed ID: 34396461
[TBL] [Abstract][Full Text] [Related]
36. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
Artifoni M; Danic G; Gautier G; Gicquel P; Boutoille D; Raffi F; Néel A; Lecomte R
J Thromb Thrombolysis; 2020 Jul; 50(1):211-216. PubMed ID: 32451823
[TBL] [Abstract][Full Text] [Related]
37. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
[TBL] [Abstract][Full Text] [Related]
38. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients.
Atallah B; Sadik ZG; Salem N; El Nekidy WS; Almahmeed W; Park WM; Cherfan A; Hamed F; Mallat J
Anaesthesia; 2021 Mar; 76(3):327-335. PubMed ID: 33047335
[TBL] [Abstract][Full Text] [Related]
39. Investigation into the Cost-Effectiveness of Extended Posttraumatic Thromboprophylaxis.
Nicholson KJ; Rosengart MR; Smith KJ; Neal MD; Myers SP
J Am Coll Surg; 2022 Jan; 234(1):86-94. PubMed ID: 35213466
[TBL] [Abstract][Full Text] [Related]
40. Prothrombotic fibrin clot properties are associated with post-discharge venous thromboembolism in acutely ill medical patients.
Wójcik M; Zaręba L; Undas A
Thromb Res; 2019 Oct; 182():141-149. PubMed ID: 31479942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
